vs
Side-by-side financial comparison of Claros Mortgage Trust, Inc. (CMTG) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $46.7M, roughly 1.5× Claros Mortgage Trust, Inc.). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -468.9%, a 419.9% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -22.4%).
Claros Mortgage Trust, Inc. is a U.S.-based real estate investment trust that invests in diversified mortgage-related assets, including residential and commercial mortgage loans and mortgage-backed securities. It pursues stable, risk-adjusted long-term returns for shareholders via rigorous asset evaluation and active portfolio management.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
CMTG vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.7M | $70.6M |
| Net Profit | $-219.2M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | -468.9% | -49.0% |
| Revenue YoY | -22.4% | 81958.1% |
| Net Profit YoY | -117.7% | 54.9% |
| EPS (diluted) | $-1.56 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $46.7M | — | ||
| Q3 25 | $46.1M | $70.6M | ||
| Q2 25 | $51.6M | — | ||
| Q1 25 | $43.4M | — | ||
| Q4 24 | $60.2M | — | ||
| Q3 24 | $64.9M | — | ||
| Q2 24 | $64.5M | — | ||
| Q1 24 | $58.8M | — |
| Q4 25 | $-219.2M | — | ||
| Q3 25 | $-9.5M | $-34.6M | ||
| Q2 25 | $-181.7M | — | ||
| Q1 25 | $-78.6M | — | ||
| Q4 24 | $-100.7M | — | ||
| Q3 24 | $-56.2M | — | ||
| Q2 24 | $-11.6M | — | ||
| Q1 24 | $-52.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -468.9% | — | ||
| Q3 25 | -20.7% | -49.0% | ||
| Q2 25 | -351.9% | — | ||
| Q1 25 | -181.3% | — | ||
| Q4 24 | -167.2% | — | ||
| Q3 24 | -86.7% | — | ||
| Q2 24 | -17.9% | — | ||
| Q1 24 | -89.7% | — |
| Q4 25 | $-1.56 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-1.30 | — | ||
| Q1 25 | $-0.56 | — | ||
| Q4 24 | $-0.72 | — | ||
| Q3 24 | $-0.40 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $173.2M | $490.9M |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $1.5B | $503.0M |
| Total Assets | $4.7B | $577.1M |
| Debt / EquityLower = less leverage | 2.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $173.2M | — | ||
| Q3 25 | $339.5M | $490.9M | ||
| Q2 25 | $209.2M | — | ||
| Q1 25 | $127.8M | — | ||
| Q4 24 | $99.1M | — | ||
| Q3 24 | $113.9M | — | ||
| Q2 24 | $148.2M | — | ||
| Q1 24 | $232.5M | — |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.7B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $4.9B | — | ||
| Q3 24 | $5.1B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.5B | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.7B | $503.0M | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $4.7B | — | ||
| Q3 25 | $5.4B | $577.1M | ||
| Q2 25 | $5.8B | — | ||
| Q1 25 | $6.7B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $7.8B | — |
| Q4 25 | 2.06× | — | ||
| Q3 25 | 2.09× | — | ||
| Q2 25 | 2.29× | — | ||
| Q1 25 | 2.42× | — | ||
| Q4 24 | 2.44× | — | ||
| Q3 24 | 2.44× | — | ||
| Q2 24 | 2.46× | — | ||
| Q1 24 | 2.47× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-30.5M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-30.5M | — | ||
| Q3 25 | $8.8M | $-84.6M | ||
| Q2 25 | $-5.8M | — | ||
| Q1 25 | $-35.8M | — | ||
| Q4 24 | $84.5M | — | ||
| Q3 24 | $39.2M | — | ||
| Q2 24 | $5.5M | — | ||
| Q1 24 | $21.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMTG
| Real Estate Owned Portfolio | $34.2M | 73% |
| Other | $11.1M | 24% |
| Mixed Use Property Fixed Rents | $1.4M | 3% |
VRDN
Segment breakdown not available.
